Status: IPO (NASDAQ: TPTX), M&A

 

Turning Point is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. Their lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. They are focused on developing therapies that mark a turning point for patients in their cancer treatment.

 

Turning Point was listed on NASDAQ in 2019 and was subsequently acquired by Bristol Myers Squibb (NYSE: BMY) in 2022.

 

To learn more, please visit: www.bms.com